Peptides targeting gastrointestinal mucosal healing, intestinal barrier integrity, and gut inflammation through distinct anti-inflammatory and tissue repair mechanisms.
Gut HealthMucosal HealingAnti-InflammatoryBarrier Function
Gut health research has identified the intestinal barrier as a critical interface between the immune system and the external environment. Barrier dysfunction (increased permeability) permits translocation of microbial products into systemic circulation, driving chronic inflammation. The peptides in this category target gut health through complementary mechanisms: BPC-157 promotes mucosal tissue repair through growth factor signaling and angiogenesis, while KPV suppresses intestinal inflammation through NF-kB inhibition and supports epithelial barrier integrity. Both address aspects of gut dysfunction that contribute to systemic health impacts.
Body protection compound originally isolated from gastric juice with extensive research in gastrointestinal healing. BPC-157 promotes mucosal repair, counteracts NSAID-induced gut damage, heals inflammatory bowel lesions, and supports intestinal anastomosis healing in preclinical models.
Anti-inflammatory tripeptide that directly inhibits NF-kB signaling in intestinal epithelial cells. Research shows oral KPV can survive gastric digestion to act on colonic tissue, reducing inflammation and supporting mucosal barrier function in colitis models.
◆ ◆ ◆
Frequently Asked Questions.
Research suggests BPC-157 promotes mucosal tissue repair and KPV supports epithelial barrier integrity, both of which are relevant to intestinal permeability. However, increased intestinal permeability is a complex condition with multiple contributing factors, and peptide research in this area is primarily preclinical.
BPC-157 is derived from a protein found in human gastric juice, suggesting inherent gastrointestinal compatibility. Extensive preclinical research shows gastrointestinal healing effects with no reported GI adverse events. However, human clinical trials for gastrointestinal indications have not been completed.
Research demonstrates that KPV survives gastric digestion and acts directly on colonic epithelial cells when administered orally. This is unusual for peptides and makes KPV particularly relevant for gut-targeted applications. Oral bioavailability for systemic effects remains limited.
Research Disclaimer: Content on PowerPeptides.co is for informational and research purposes only. It is not medical advice. Peptides discussed are research compounds unless explicitly noted as FDA-approved. Always consult a licensed healthcare provider before beginning any peptide protocol. Full Disclaimer | Affiliate Disclosure